FDA on Wednesday (Feb. 6) finalized guidance detailing the types of clinical studies and novel endpoints that can be used to support approval of depot buprenorphine products and how sponsors should design efficacy trials. The guidance is part of the agency’s efforts to encourage widespread use and coverage of FDA-approved medication-assisted treatment (MAT), agency head Scott Gottlieb said in a press statement on Wednesday. On Wednesday, Gottlieb stressed an urgent need for better treatment options for opioid use disorder (OUD)...